Viking Global Investors LP Intellia Therapeutics, Inc. Transaction History

Viking Global Investors LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$33.3 - $44.82 $15 Million - $20.3 Million	-451,865 Reduced 22.35%	1,569,545 $58.5 Million
Q4 2022 Feb 14, 2023	BUY	$33.21 - $62.69 $4.4 Million - $8.3 Million	132,343 Added 7.01%	2,021,410 $70.5 Million
Q3 2022 Nov 14, 2022	SELL	$53.92 - $71.7 $18.3 Million - $24.3 Million	-339,316 Reduced 15.23%	1,889,067 $106 Million
Q2 2022 Aug 15, 2022	SELL	$38.49 - $76.21 $9.25 Million - $18.3 Million	-240,377 Reduced 9.74%	2,228,383 $115 Million
Q1 2022 May 16, 2022	BUY	$58.27 - $118.99 $51.8 Million - $106 Million	889,224 Added 56.3%	2,468,760 $179 Million
Q4 2021 Feb 14, 2022	BUY	$100.76 - $138.36 $30.2 Million - $41.5 Million	300,005 Added 23.45%	1,579,536 $187 Million
Q3 2021 Nov 15, 2021	BUY	$132.37 - $176.78 $40.3 Million - $53.8 Million	304,439 Added 31.22%	1,279,531 $172 Million
Q2 2021 Aug 16, 2021	BUY	$60.88 - $161.91 $59.4 Million - $158 Million	975,092 New	975,092 $158 Million

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $926M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Viking Global Investors LP, based on Form 13F filings with the SEC.

Stay updated on Viking Global Investors LP with notifications on news.